Genentech, a member of the Roche Group, is set to present new data from its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference® 2026 in London on July 12-15. These findings showcase the companies’ ongoing commitment to developing next-generation treatments and diagnostic tests aimed at slowing or stopping the progression of Alzheimer’s disease.
Subscribe
Biotechnology
Chronic Illness Management
Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC
Key Takeaways:
- Genentech and Roche will present new Alzheimer’s disease data at AAIC 2026.
- Their approach combines pharmaceuticals and diagnostics for maximum impact.
- The companies’ research aims to slow or halt dementia’s progression.
- There are 18 oral presentations referenced, though details are limited.
- This work reflects a mission to advance scientific understanding and patient outcomes.
The Global Stage for Alzheimer’s Advances
Genentech and Roche are preparing to unveil a new wave of data on Alzheimer’s disease at the Alzheimer’s Association International Conference® 2026 (AAIC®) in London from July 12 to July 15. AAIC represents a key gathering for scientists and clinicians worldwide who share a commitment to combatting Alzheimer’s through collaboration and knowledge exchange.
A Portfolio of Progress
As a member of the Roche Group, Genentech has expanded its Alzheimer’s disease portfolio through an integrated pharmaceutical and diagnostics platform. According to the announcement, these developments are intended to pave the way for novel testing methods and more efficient treatments that could potentially transform how the disease is diagnosed and managed.
Aiming to Slow or Stop Alzheimer’s
In this latest update, Genentech and Roche emphasize their underlying mission: slowing, stopping, or even preventing the progression of Alzheimer’s disease. Their work draws attention to the disease’s complexity, highlighting the need not just for therapeutic interventions, but also for innovative diagnostic tools that identify symptoms earlier and more accurately.
Looking Ahead
While the details on the 18 oral presentations remain limited, the overall message is clear. By combining new medicines with advanced testing, Genentech and Roche hope to expand scientific understanding and potentially improve outcomes for millions of people affected by Alzheimer’s disease. Their efforts at AAIC 2026 reflect a broader goal: to continue advancing research that can revolutionize care for patients worldwide.
